New vascular disease target found

CVD Study finds high level of Lp-PLA2 protein in blood is associated with raised CHD risk.

Atherosclerotic plaques are the source of the enzyme Lp-PLA2 (Southern Illinois University/SPL)
Atherosclerotic plaques are the source of the enzyme Lp-PLA2 (Southern Illinois University/SPL)

A protein found in blood has been shown to predict CHD risk as accurately as cholesterol and BP levels, suggesting it could be targeted to prevent vascular disease.

A UK study showed that the enzyme lipoprotein-associated phospholipase A2 (Lp-PLA2) increased the risk of CHD, stroke and vascular death. The increased risk of CHD was similar to that caused by high non-HDL cholesterol and high BP.

Researchers from the University of Cambridge said the findings reinforced interest in the enzyme as a potential target for preventing heart disease.

Lp-PLA2 is secreted by atherosclerotic plaques and has been found to produce pro-inflammatory compounds implicated in vascular disease. The study is the first to examine the enzyme's role as a risk factor for CHD, stroke and mortality.

Researchers led by Dr Alex Thompson examined data from 79,036 patients from 32 studies of vascular disease, including measurements of Lp-PLA2 levels in the blood. The patient population included healthy individuals, patients with a history of stable vascular disease and patients who had suffered a recent acute ischaemic event.

Analysis of the data uncovered 17,722 vascular events and deaths, which the researchers studied to calculate risk ratios for Lp-PLA2. Primary outcome was CHD; stroke and vascular death were secondary outcomes.

The researchers found that higher levels of Lp-PLA2 were associated with a raised risk of CHD and stroke. The risk linked with Lp-PLA2 was independent of other inflammatory markers, such as C-reactive protein.

Measurements of the enzyme could therefore offer a new insight into the role of inflammation in the development of CHD, the authors said.

Dr Thompson concluded: 'Randomised clinical trials of Lp-PLA2 inhibitors should help establish whether lowering Lp-PLA2 levels can reduce risk of vascular disease.'

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Face-to-face GP appointments on demand 'unachievable', warns RCGP chair

Face-to-face GP appointments on demand 'unachievable', warns RCGP chair

Calls for general practice to offer face-to-face appointments to all patients who...

Cornwall PCN wheels out electric car fleet to reduce carbon footprint

Cornwall PCN wheels out electric car fleet to reduce carbon footprint

Staff at a primary care network (PCN) in Cornwall have committed to reducing their...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

Repeat prescribing and SMR overhaul as review finds one in 10 scrips unnecessary

Repeat prescribing and SMR overhaul as review finds one in 10 scrips unnecessary

Repeat prescribing and use of structured medication reviews in general practice are...

BMA demands emergency meeting with government over GP abuse

BMA demands emergency meeting with government over GP abuse

BMA leaders have requested an emergency summit with the government to discuss ‘unacceptable...

Millions of pounds lost to general practice as flagship recruitment scheme falls short

Millions of pounds lost to general practice as flagship recruitment scheme falls short

Tens of millions of pounds in funding from a flagship recruitment scheme set up to...